Gilbert AZ 非小细胞肺癌临床试验
12项针对 非小细胞肺癌的研究正在 Gilbert及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- Banner MD Anderson Cancer Center ( Site 0181), Gilbert
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
招募中1 期
- Research Site, Gilbert
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Ironwood Cancer & Research Centers, Gilbert
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
招募中观察性研究
- Banner Health, Gilbert
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
招募中1/2 期
- Banner MD Anderson Cancer Center, Gilbert
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- Banner Health- MD Anderson Cancer Center, Gilbert
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Banner MD Anderson Cancer Center, Gilbert
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
招募中3 期
- Research Site, Gilbert
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
招募中1/2 期
- Banner MD Anderson Cancer Center, Gilbert
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- Banner Health MD Anderson, Gilbert
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
招募中1/2 期
- Banner Health, Gilbert
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
招募中1/2 期
- Banner MD Anderson Cancer Center, Gilbert
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY120 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH56 项研究
- Washington, DC55 项研究
Gilbert的其他研究
- 结直肠癌9 项研究
- 乳腺癌9 项研究
- 肺癌8 项研究
- 癌症(所有类型)8 项研究
- 头颈鳞状细胞癌6 项研究
- 转移性癌症6 项研究
- 多发性骨髓瘤6 项研究
- 心力衰竭6 项研究
- 心血管疾病6 项研究
- 膀胱癌6 项研究
- 非霍奇金淋巴瘤5 项研究
- 弥漫性大B细胞淋巴瘤5 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月5日。每项研究自行设定入选标准,由研究团队决定谁能参与。